Related references
Note: Only part of the references are listed.Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients
Z. Sun et al.
ANNALS OF ONCOLOGY (2010)
MDR1 C2005T polymorphism changes substrate specificity
Lijuan Liu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide
Jurjen S. Lagas et al.
CLINICAL CANCER RESEARCH (2010)
Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
Kazuma Kiyotani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacogenetics of Membrane Transporters: An Update on Current Approaches
Tristan M. Sissung et al.
MOLECULAR BIOTECHNOLOGY (2010)
Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients
Phillip J. Mueller et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia
Kazuma Kiyotani et al.
CANCER SCIENCE (2008)
A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms
Xiaoyi Gao et al.
GENETIC EPIDEMIOLOGY (2008)
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol
Sierk Haenisch et al.
PHARMACOGENETICS AND GENOMICS (2008)
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
Ji-Youn Han et al.
CANCER (2007)
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Functional SNPs of the breast cancer resistance protein - therapeutic effects and inhibitor development
K Yanase et al.
CANCER LETTERS (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer
JW Sohn et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2006)
Efficiency and power in genetic association studies
PIW de Bakker et al.
NATURE GENETICS (2005)
Pharmacogenetics for individualized cancer chemotherapy
T Efferth et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Haploview: analysis and visualization of LD and haplotype maps
JC Barrett et al.
BIOINFORMATICS (2005)
Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix
J Li et al.
HEREDITY (2005)
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2
S Mizuarai et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer
K Yoh et al.
CLINICAL CANCER RESEARCH (2004)
The changing epidemiology of lung cancer in Europe
MLG Janssen-Heijnen et al.
LUNG CANCER (2003)
P14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice
B Eymin et al.
ONCOGENE (2003)
Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition
H Suzuki et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer
FJ Kaye
ONCOGENE (2002)
Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays
GE Sandusky et al.
HISTOPATHOLOGY (2002)
The structure of haplotype blocks in the human genome
SB Gabriel et al.
SCIENCE (2002)
Multidrug resistance related molecules in human and murine lung
GL Scheffer et al.
JOURNAL OF CLINICAL PATHOLOGY (2002)
Frequent and histological type-specific inactivation of 14-3-3σ in human lung cancers
H Osada et al.
ONCOGENE (2002)
Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma
B Eymin et al.
ONCOGENE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
